Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of different teprotumumab dosing durations in thyroid eye disease
2020-005999-36Phase 3Active
- Sponsor
- Horizon Therapeutics
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of teprotumumab in Graves Orbitopathy (GO) and Graves' ophthalmopathy (TED) (3 arms), sponsored by Horizon Therapeutics. Primary endpoint: Treatment-emergent adverse events and adverse events of special interest. Started Nov 2021; status: active.
02
Drugs
teprotumumab
03
Conditions
Graves Orbitopathy (GO)Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on 2020-005999-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005999-36.